The only FDA-licensed smallpox vaccine, ACAM2000 (Smallpox (Vaccinia) Vaccine, Live), will be acquired from Sanofi by Emergent BioSolutions under a recently announced deal. The move expands and diversifies Emergent’s portfolio of medical [Read more]
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, has awarded $46.6 million in [Read more]
Emergent BioSolutions Inc. held a ribbon-cutting ceremony last week on May 10 to mark the formal opening of the company’s newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) at its Bayview Campus in Baltimore. [Read more]
A pilot study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) of an investigational medical countermeasure for Acute Radiation Syndrome (ARS) has shown promising results. ARS occurs following acute [Read more]
Soligenix, Inc. announced today that it has been granted a Japanese patent (number 6110845) further extending protection around ThermoVax including coverage of the company’s ricin toxin vaccine candidate, RiVax. The technology is [Read more]
Battelle and Nanotherapeutics, Inc. announced today that the organizations have entered an alliance to bring together core research, development, test and evaluation (RDT&E) and manufacturing capabilities needed to expedite the development of [Read more]
Battelle’s Hazardous Materials Research Center (HMRC) will host a Live-Agent Test Week April 17-21, 2017. The event is an opportunity for manufacturers and developers of personal protective equipment against Chemical, Biological, Radiological [Read more]
DynPort Vaccine Company LLC, a subsidiary of CSRA Inc., this week announced it has been granted Orphan Drug Designation for its recombinant rF1V plague vaccine from the U.S. Food and Drug Administration [Read more]
A Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B has been initiated by Emergency BioSolutions, according to an announcement by the company on Feb 1. UV-4B [Read more]
PaxVax last week announced a partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its chikungunya vaccine program. The company has in-licensed NIH’s virus-like particle (VLP) vaccine technology [Read more]
© 2017 Global Biodefense